Overall, 633 single-source brands take a price hike
FAYETTEVILLE, NY, UNITED STATES, February 2, 2022 /EINPresswire.com/ — After having over 600 single-source brand name drugs take price increases during the first three weeks of January, at an average increase of 5.05%, drug manufacturers continued this trend by increasing an additional 31 brands, having an average increase of 5.63%. These latest price increases range from a high of 7.40% for both Enbrel [Amgen] – used as a treatment for rheumatoid arthritis, and Otezla [Amgen] – used for the treatment of adult patients with psoriatic arthritis, to a low of 3.0% for Lumakras [Amgen] – used to treat a certain type of lung cancer, Serostim [Serono] – used for the treatment of HIV patients with certain conditions, and Saizen [Serono] – used to treat growth failure in both children and adults.
Additional brands taking price increases in the final week of January include Blincyto [Amgen] – used to treat a certain type of cancer, at 5.90%, Ovidrel [Serono] – used as part of a treatment program for certain fertility problems, at 6.50%, and Krystexxa [Horizon Therape] – used to treat gout, at 4.80%.
Overall, January has seen price increases for 633 single-source brand name drugs taking an average of 5.08%. These increases range from a high of 25.00% for Atgam [Pfizer], used to treat moderate to severe aplastic anemia, to a low of 0.75% for Adakveo [Novartis], used to treat sickle cell disease in patients 16+ years of age.
When grouping brands into their respective therapeutic class for January, analgesics had the highest percent increase at 9.54%, followed by sedatives & hypnotics and antihyperlipidemic agents at 7.27% and 7.20% respectively. Anesthetics had the lowest percent increase at 1.18% (See chart).
It is important to note that overall inflation for 2021 was 7.0% to provide context for the drug price increases.
Source
AnalySource® as of Feb 1, 2022 – Reprinted with permission by First Databank, Inc. All rights reserved. © 2022
* First Databank, Inc Drug Pricing Policy: https://www.fdbhealth.com/drug-pricing-policy
About DMD America, Inc
AnalySource® is a registered trademark and drug pricing data solution service of DMD America, Inc. Since 1996, data has been made available in cooperation with First Databank, Inc. a subsidiary of the Hearst Corporation. Our service is licensed by subscription, with global clients including biotech, pharmaceuticals, government agencies, consultancies, academia, and more.
About First Databank (FDB)
First Databank (FDB) is the leading provider of drug and medical device knowledge that helps healthcare professionals make precise decisions. We empower our information system developer partners to deliver valuable, useful, and differentiated solutions used by millions of clinicians, business associates, and patients every day. For more than four decades, our medical knowledge has helped improve patient safety, operational efficiency, and healthcare outcomes. For a complete look at our solutions and services, please visit www.fdbhealth.com.
Eric Tedford
DMD America, Inc
+1 315-671-4208
email us here
